Blood News and Research

RSS

CeNeRx BioPharma's TriRima reversibly inhibits MAO-A, confirms PET imaging study

CeNeRx BioPharma, Inc., a clinical stage company developing innovative treatments for diseases of the central nervous system, today announced that a newly published PET imaging study in human subjects confirms that CeNeRx's novel compound TriRima(TM) reversibly inhibits MAO-A (monoamine oxidase A), an enzyme in the brain that plays a key role in the regulation of mood.

8 Dec 2009

Positive data from ARIAD Pharmaceuticals' ongoing AP24534 study in advanced hematological cancer patients

ARIAD Pharmaceuticals, Inc. today announced positive clinical data from an ongoing Phase 1 study of its investigational, pan-BCR-ABL inhibitor, AP24534, in patients with advanced hematological cancers.

8 Dec 2009

Phase III CLL8 trial shows Rituxan plus FC chemotherapy improves patients with CLL

Genentech, Inc., a wholly owned member of the Roche Group, and Biogen Idec today announced that three-year follow up of the pivotal Phase III CLL8 trial showed Rituxan plus fludarabine and cyclophosphamide (FC) chemotherapy helped patients in the trial with previously untreated chronic lymphocytic leukemia (CLL) live longer than FC alone.

8 Dec 2009

LCA-GA praises Senators' support in establishing comprehensive program for lung cancer

Today, Lung Cancer Alliance-Georgia (LCA-GA) acknowledged Senators Saxby Chambliss (R-GA) and Johnny Isakson (R-GA) for their leadership and support in establishing the first ever multi-agency, comprehensive program targeted at lung cancer.

8 Dec 2009

Excess radiation exposure during CT perfusion imaging: FDA issues interim recommendations

As part of an ongoing investigation into cases of excess radiation during CT perfusion imaging of the brain, the U.S. Food and Drug Administration today provided imaging facilities and practitioners with interim recommendations to help prevent additional problems.

8 Dec 2009

Study: Besides nerves, skin has a unique sensory system

The human sensory experience is far more complex and nuanced than previously thought, according to a groundbreaking new study published in the December 15, 2009 issue of the journal Pain (http://www.painjournalonline.com/article/S0304-3959%2809%2900526-0/abstract).

8 Dec 2009

New genetic approach may hold promise for sickle cell disease

A new genetic approach to treating sickle cell disease is showing promising results in mice, report researchers from Children's Hospital Boston. By inactivating a gene they previously discovered to be important in the laboratory, they were able to boost production of a healthy fetal form of hemoglobin in the mice, potentially compensating for the defective adult hemoglobin that causes red blood cells to "sickle" and obstruct blood flow.

8 Dec 2009

ERSPC study shows PSA screening reduced prostate cancer deaths by 20%

The effectiveness of PSA (prostate-specific antigen) screening on reducing prostate cancer mortality has been given a boost with new data from the European Randomized Study of Screening for Prostate Cancer (ERSPC). This shows the true impact to be far higher than previously reported - up to 31%.

8 Dec 2009

MicroPhage obtains CE mark to market MRSA/MSSA Blood Culture Test in Europe

MicroPhage announced today that it has obtained its CE Mark to market in Europe the first of its instrument-free, rapid tests based on its patented Bacteriophage Amplification technology.

8 Dec 2009

JAK2 inhibitor can control myelofibrosis, report researchers

A first-in-its class oral medication provides significant and durable relief for patients with a rare, debilitating and lethal bone marrow disorder called myelofibrosis, researchers at The University of Texas M. D. Anderson Cancer Center reported today at the 51st Annual Meeting of the American Society of Hematology.

8 Dec 2009

Defibrotide drug effective against hepatic veno-occlusive disease

Defibrotide, a novel drug which modulates the response of blood vessels to injury, was markedly more effective than standard treatment in post-stem cell transplant patients with hepatic veno-occlusive disease, a life threatening toxicity of transplant caused by blockages in tiny blood vessels of the liver, according to a study led by Dana-Farber Cancer Institute scientists.

8 Dec 2009

Geisinger installs catheter-based cardiac assist device, Impella 2.5

A minimally invasive, catheter-based cardiac assist device - the Impella 2.5 - is credited with saving the life of 86-year-old Rose Lombardo of Hazleton. Grandmother to seven and great-grandmother to another 12, Rose was "at death's door" after suffering concurrent heart attacks, according to her daughter, Gabriella Norgard.

8 Dec 2009

Human blood stem cells can be engineered to kill HIV-infected cells, find researchers

Researchers from the UCLA AIDS Institute and colleagues have for the first time demonstrated that human blood stem cells can be engineered into cells that can target and kill HIV-infected cells — a process that potentially could be used against a range of chronic viral diseases.

8 Dec 2009

Potentially promising data from Phase I/II study of elotuzumab presented at ASH 2009

Facet Biotech Corporation and Bristol-Myers Squibb Company announced that potentially promising data from a Phase I/II study of elotuzumab, an investigational humanized antibody being studied for the treatment of relapsed multiple myeloma (MM), were presented today at the American Society of Hematology (ASH) 2009 Annual Meeting in New Orleans.

8 Dec 2009

Abstracts on very small embryonic-like stem cells presented at ASH annual meeting

NeoStem, Inc., which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need and holds the exclusive, worldwide license to VSEL(TM) technology that uses very small embryonic-like stem cells isolated from peripheral blood, announced today that an abstract authored by NeoStem-affiliated scientists was presented in a poster presentation at the prestigious American Society of Hematology (ASH) Annual Meeting in New Orleans on December 5, 2009.

8 Dec 2009

PolyMedix to present data on its heptagonist compounds

PolyMedix, Inc. (http://polymedix.com), an emerging biotechnology company developing acute care therapeutic drug products for infectious diseases and cardiovascular disorders, announced that data will be presented on its heptagonist compounds at the annual meeting of the American Society of Hematology in New Orleans, Louisiana.

8 Dec 2009

People infected with West Nile virus may have persistent virus in their kidneys, shows study

A new study shows that people who have been infected with West Nile virus may have persistent virus in their kidneys for years after initial infection, potentially leading to kidney problems.

8 Dec 2009

Data shows strong inverse association between coffee consumption and advanced prostate cancer

While it is too early for physicians to start advising their male patients to take up the habit of regular coffee drinking, data presented at the American Association for Cancer Research Frontiers in Cancer Prevention Research Conference revealed a strong inverse association between coffee consumption and the risk of lethal and advanced prostate cancers.

8 Dec 2009

Amgen announces results from first Phase 1/2 study of Nplate

Amgen Inc. today announced results from its first Phase 1/2 study evaluating the safety and efficacy of Nplate® (romiplostim) in children with chronic immune thrombocytopenic purpura (ITP).

8 Dec 2009

Young adults with higher blood lead levels more likely to have panic disorders, reveals research

Young adults with higher blood lead levels appear more likely to have major depression and panic disorders, even if they have exposure to lead levels generally considered safe, according to a report in the December issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

8 Dec 2009

Blood News and Research

CeNeRx BioPharma's TriRima reversibly inhibits MAO-A, confirms PET imaging study

Positive data from ARIAD Pharmaceuticals' ongoing AP24534 study in advanced hematological cancer patients

Phase III CLL8 trial shows Rituxan plus FC chemotherapy improves patients with CLL

LCA-GA praises Senators' support in establishing comprehensive program for lung cancer

Excess radiation exposure during CT perfusion imaging: FDA issues interim recommendations

Study: Besides nerves, skin has a unique sensory system

New genetic approach may hold promise for sickle cell disease

ERSPC study shows PSA screening reduced prostate cancer deaths by 20%

MicroPhage obtains CE mark to market MRSA/MSSA Blood Culture Test in Europe

JAK2 inhibitor can control myelofibrosis, report researchers

Defibrotide drug effective against hepatic veno-occlusive disease

Geisinger installs catheter-based cardiac assist device, Impella 2.5

Human blood stem cells can be engineered to kill HIV-infected cells, find researchers

Potentially promising data from Phase I/II study of elotuzumab presented at ASH 2009

Abstracts on very small embryonic-like stem cells presented at ASH annual meeting

PolyMedix to present data on its heptagonist compounds

People infected with West Nile virus may have persistent virus in their kidneys, shows study

Data shows strong inverse association between coffee consumption and advanced prostate cancer

Amgen announces results from first Phase 1/2 study of Nplate

Young adults with higher blood lead levels more likely to have panic disorders, reveals research

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News